Atlas Capital Advisors Inc. Sells 20,625 Shares of Organon & Co. (NYSE:OGN)

Atlas Capital Advisors Inc. decreased its holdings in Organon & Co. (NYSE:OGN) by 85.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,546 shares of the company’s stock after selling 20,625 shares during the quarter. Atlas Capital Advisors Inc.’s holdings in Organon & Co. were worth $53,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Barclays PLC boosted its stake in shares of Organon & Co. by 238.0% during the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after acquiring an additional 84,136 shares during the last quarter. Robeco Institutional Asset Management B.V. bought a new stake in Organon & Co. during the fourth quarter valued at about $2,263,000. Wedmont Private Capital increased its position in Organon & Co. by 453.4% in the fourth quarter. Wedmont Private Capital now owns 100,539 shares of the company’s stock worth $1,594,000 after buying an additional 82,372 shares in the last quarter. Sippican Capital Advisors raised its stake in shares of Organon & Co. by 138.7% in the fourth quarter. Sippican Capital Advisors now owns 36,352 shares of the company’s stock worth $542,000 after buying an additional 21,122 shares during the period. Finally, Systematic Financial Management LP lifted its position in shares of Organon & Co. by 5,097.3% during the 3rd quarter. Systematic Financial Management LP now owns 37,940 shares of the company’s stock valued at $726,000 after buying an additional 37,210 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on OGN shares. Morgan Stanley reduced their target price on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Organon & Co. currently has a consensus rating of “Hold” and an average price target of $20.80.

Organon & Co. Trading Down 9.8 %

Shares of OGN opened at $13.04 on Friday. The firm has a market cap of $3.36 billion, a P/E ratio of 3.91, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. Organon & Co. has a 1 year low of $13.00 and a 1 year high of $23.10. The company has a 50 day simple moving average of $15.16 and a two-hundred day simple moving average of $16.02.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, equities analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 8.59%. Organon & Co.’s dividend payout ratio is currently 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.